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G protein–coupled receptor kinase 2 (GRK2) is 
localized to centrosomes and mediates epidermal 
growth factor–promoted centrosomal separation
Christopher H. So, Allison Michal*, Konstantin E. Komolov, Jiansong Luo, and Jeffrey L. Benovic
Department of Biochemistry and Molecular Biology, Thomas Jefferson University, Philadelphia, PA 19107
ABSTRACT G protein–coupled receptor kinases (GRKs) play a central role in regulating 
receptor signaling, but recent studies suggest a broader role in modulating normal 
cellular functions. For example, GRK5 has been shown to localize to centrosomes and 
regulate microtubule nucleation and cell cycle progression. Here we demonstrate that 
GRK2 is also localized to centrosomes, although it has no role in centrosome duplication 
or microtubule nucleation. Of interest, knockdown of GRK2 inhibits epidermal growth 
factor receptor (EGFR)–mediated separation of duplicated centrosomes. This EGFR/
GRK2-mediated process depends on the protein kinases mammalian STE20-like kinase 2 
(Mst2) and Nek2A but does not involve polo-like kinase 1. In vitro analysis and dominant-
negative approaches reveal that GRK2 directly phosphorylates and activates Mst2. Col-
lectively these findings demonstrate that GRK2 is localized to centrosomes and plays a 
central role in mitogen-promoted centrosome separation most likely via its ability to 
phosphorylate Mst2.
INTRODUCTION
G protein–coupled receptor kinases (GRKs) are a family of seven 
protein kinases that phosphorylate agonist-occupied G protein–
coupled receptors (GPCRs), thereby linking agonist binding with 
regulatory processes such as desensitization and internalization 
(Moore et al., 2007). Of interest, many studies revealed that GRKs 
have additional functions beyond regulating GPCRs (Gurevich 
et al., 2012). For example, GRKs phosphorylate and regulate the 
function of many additional proteins, including tubulin (Carman 
et al., 1998; Pitcher et al., 1998), NHERF (Hall et al., 1999), 
synucleins (Pronin et al., 2000), phosducin (Ruiz-Gomez et al., 
2000), platelet-derived growth factor and epidermal growth factor 
receptors (Freedman et al., 2002), ezrin (Cant and Pitcher, 2005), 
p38 (Peregrin et al., 2006), NFκB1 p105 (Parameswaran et al., 
2006), HDAC5 (Martini et al., 2008), IκBα (Patial et al., 2009), β-
arrestin-1 (Barthet et al., 2009), p53 (Chen et al., 2010), Hip (Barker 
and Benovic, 2012), nucleophosmin (So et al., 2012), and many 
others. GRKs have also been linked with a number of diseases, 
including various neurological disorders (Suo et al., 2007; Bychkov 
et al., 2008, 2011; Garcia-Sevilla et al., 2010), cardiovascular dis-
ease (Ungerer et al., 1993; Gros et al., 1997; Huang et al., 2012), 
and cancer (Matsubayashi et al., 2008; Tiedemann et al., 2010; 
Kim et al., 2012; Woerner et al., 2012).
Whereas GRK-mediated phosphorylation by GPCRs occurs at 
the plasma membrane, GRKs are also localized in other areas of 
the cell, such as the nucleus (Yi et al., 2002; Johnson et al., 2004), 
mitochondria (Fusco et al., 2012), and centrosomes (Michal et al., 
2012). In the nucleus, GRK5 mediates histone deacetylation to 
regulate the activity of the transcription factor MEF2 (Martini 
et al., 2008), whereas in the mitochondria, GRK2 controls ATP ac-
cumulation and tolerance to ischemia in skeletal muscle (Fusco 
et al., 2012). GRK5 localization in the centrosome regulates the 
G2/M-phase transition of the cell cycle by phosphorylating p53 
(Michal et al., 2012).
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We next evaluated the characteristics of centrosomal GRK2. 
First, we studied more detailed centrosomal localization (centriolar 
vs. pericentriolar). GRK2 was localized to both centrioles, detected 
by green fluorescent protein (GFP)–centrin (Figure 2A, top), as well 
as to pericentriolar material, indicated by pericentrin staining (Figure 
2A, bottom). GRK2 was also predominantly localized to mother cen-
trioles compared with daughter centrioles, as determined by the 
differential extent of GFP-centrin staining (Figure 2B). To assess 
whether microtubules had a role in GRK2 localization to cen-
trosomes, we treated cells with nocodazole to disrupt microtubules. 
Nocodazole treatment did not affect GRK2 centrosomal localization 
(Figure 2, C and D), suggesting that a microtubule-independent 
process is involved in this localization.
Next we determined whether GRK2 has any role in the regula-
tion of centrosomal functions such as microtubule nucleation, cen-
trosome duplication at S phase, or separation of duplicated cen-
trosomes during the cell cycle. Stable knockdown of GRK2 
expression in HeLa cells showed no discernible effect on microtu-
bule nucleation, as demonstrated by no differences in aster growth 
between GRK2-knockdown and control cells (Supplemental Figure 
S1, A and B). These findings are in contrast to GRK5, for which 
knockdown revealed an important role for GRK5 in microtubule nu-
cleation (Michal et al., 2012). Additional studies revealed no effect 
on centrosome duplication in either GRK2 shRNA or GRK5 shRNA 
cells compared with control cells (Supplemental Figure S1, C and D). 
Furthermore, no differences were observed in centrosome separa-
tion in asynchronized control, GRK2, or GRK5 shRNA cells (Supple-
mental Figure S1E). Centrosome separation was also determined 
after synchronization in G1/S by double-thymidine block (t = 0 h), 
followed by progression into G2/M (t = 6–8 h). As cells progress 
through the cell cycle, the percentage of cells showing separated 
centrosomes or cells in mitosis (separated centrosomes with con-
densed DNA) were unchanged in GRK2 shRNA cells compared with 
control cells (Supplemental Figure S1F). There does, however, ap-
pear to be a trend toward an increase in the number of cells in mito-
sis during the time course in the GRK2 shRNA HeLa cells compared 
with control cells. This may reflect increased cell cycle progression 
due to decreased GRK2 levels, as previously reported (Penela et al., 
2010).
Among the many activities mediated by epidermal growth fac-
tor receptors (EGFRs) is the ability to promote rapid separation of 
duplicated centrosomes (Sherline and Mascardo, 1982a). Although 
this function may play a role in coordinately regulating mitogen-
promoted centrosome separation and DNA synthesis (Sherline and 
Mascardo, 1984), the mechanism of this process is poorly under-
stood. Because EGFR activation promotes the phosphorylation and 
activation of GRK2 (Chen et al., 2008) and GRK2 is localized to cen-
trosomes (Figures 1 and 2), we hypothesized that GRK2 might con-
tribute to the EGFR pathway that mediates centrosome separation. 
To test this possibility, we synchronized control, GRK2, and GRK5 
shRNA HeLa cells in G1/S by treating the cells with hydroxyurea for 
48 h and then incubating the cells with or without EGF. Activation of 
the EGFR was comparable in all three lines as assessed by EGF-
promoted phosphorylation of ERK1/2 and MEK1 after a 5-min treat-
ment with EGF (Figure 3A). This result is in agreement with previous 
studies showing that GRK2 expression does not change EGFR activ-
ity (Freedman et al., 2002). Centrosome separation was determined 
by counting cells that displayed duplicated centrosomes greater 
than one centrosome diameter apart, and this was then expressed 
as a percentage of the total cells. Control and GRK5 shRNA cells 
demonstrated similar approximately twofold increase in the number 
of cells with centrosomal separation after 30-min EGF treatment, 
A number of protein kinases localized in the centrosome are criti-
cal for the G2 and M phases of the cell cycle by properly orienting 
centrosomes to regulate the mitotic spindle (Bettencourt-Dias and 
Glover, 2007). Centrosome-localized kinases also regulate activities 
of the centrosomes themselves. For example, Nek2A controls a pro-
cess at G2 known as centrosomal disjunction or separation. In this 
process, a protein linker, made up of rootletin and C-Nap1, con-
nects the proximal end of the two mother centrioles of the dupli-
cated centrosomes. During late G2 phase, polo-like kinase 1 (Plk1) 
phosphorylates the proapoptotic protein kinase mammalian STE20-
like kinase 2 (Mst2), which then phosphorylates and activates Nek2A, 
resulting in inhibition of PP1γ interaction with the Mst2-Nek2A com-
plex (Mardin et al., 2011). Activated Nek2A then phosphorylates C-
Nap1, initiating a mechanism that untethers duplicated centrosomes 
(Mardin et al., 2010). After disjunction, centrosomes separate and 
move to opposite poles through the activity of the microtubule-de-
pendent motor protein Eg5 and form the mitotic spindle (Smith 
et al., 2011). Errors in this process can lead to monopolar and multi-
polar mitotic spindles. For example, cells with incomplete spindle 
pole separation exhibit higher rates of kinetochore misattachment 
and chromosome missegregation than cells with properly timed and 
complete centrosome separation (Silkworth et al., 2012). These de-
fects can cause genomic instability (Ganem et al., 2009) and the de-
velopment of cancer (Basto et al., 2008).
In this article, we analyze the cellular localization and function of 
GRK2. GRK2 is localized to centrosomes and plays a critical role in 
mediating epidermal growth factor receptor (EGFR)–promoted sep-
aration of duplicated centrosomes. This separation also uses the ki-
nases Nek2A and Mst2 but is independent of Plk1 function. We 
propose a model in which activated EGFR leads to GRK2 activation, 
which phosphorylates Mst2, resulting in activation of Nek2A, phos-
phorylation of C-Nap1, and centrosome separation.
RESULTS
Because GRK5 was previously shown to be localized in centrosomes 
and play a role in cell cycle regulation (Michal et al., 2012), we were 
interested in determining whether GRK2 is also localized in cen-
trosomes. Initial analysis of GRK2 expression in HeLa, HEK293, and 
MDA-MB-231 cells demonstrated that all three lines express GRK2, 
with HEK293 cells having the highest level and HeLa cells the lowest 
(Figure 1A). To assess whether any endogenous GRK2 is localized in 
centrosomes, we first preextracted cells with detergent for 30 s and 
then fixed, permeabilized, incubated them with specific antibodies 
and analyzed them by immunofluorescence microscopy. These 
studies revealed that GRK2 colocalizes with the centrosomal marker 
γ-tubulin in ∼80–90% of cells (∼90% for HEK293 and MDA-MB-231; 
∼80% for HeLa), suggesting that some GRK2 is localized in cen-
trosomes (Figure 1B). To confirm these observations, we fraction-
ated HEK293 cell lysates on a sucrose density gradient to isolate 
centrosomes and then probed them for GRK2 and α-tubulin by im-
munoblotting. GRK2 was found in the same fractions as α-tubulin, 
supporting its association with centrosomes (Figure 1C). To verify 
that the GRK2 antibody was specifically detecting endogenous 
GRK2, we stably knocked down GRK2 expression in HeLa cells by 
short hairpin RNA (shRNA) and then analyzed them by immunofluo-
rescence. The ∼75% decrease in GRK2 expression detected by im-
munoblotting in GRK2 shRNA cells resulted in a nearly complete 
loss of GRK2 staining in centrosomes (Figure 1D). Further verifica-
tion of GRK2 localization in centrosomes was achieved using a poly-
clonal GRK2-selective antibody (Figure 1E). Overall these data 
demonstrate that a portion of the endogenous GRK2 is localized in 
centrosomes.
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important in this process (Figure 3E). We also evaluated whether 
GRK2 remains localized to centrosomes after EGF-promoted sepa-
ration and found that GRK2 levels are not significantly different in 
separated centrosomes compared with unseparated centrosomes 
(Figure 3F). Thus it does not appear that EGFR activation signifi-
cantly changes the localization of GRK2 in centrosomes.
To further quantify these effects, we measured the distance be-
tween centrosomes within centrosomal pairs. Although there was 
significant increase in the number of cells with separated cen-
trosomes (from 0–2 to ≥6 μm) after a 30-min treatment with EGF, 
centrosome separation was blocked in the GRK2 shRNA cells 
(Supplemental Figure S3, A–C). To make sure that our results were 
not due to cellular changes induced by the stable knockdown of 
GRK2, we also evaluated HeLa cells with transient knockdown of 
GRK2 or GRK5 using specific small interfering RNA (siRNA) pools 
whereas EGF had no effect in the GRK2 shRNA cells (Figure 3B). To 
assess whether the EGF-promoted centrosome separation was due 
to rapid cell cycle progression, we collected cells for cell cycle anal-
ysis after a 30-min EGF treatment. No significant difference in cells 
in G1, S, or G2 phase was observed with or without EGF treatment 
(Supplemental Figure S2). Centrosome separation was rapid and 
could be observed in 40–50% of the cells after 45–60 min of EGF 
treatment (Figure 3C), values comparable to those in previous 
reports (Sherline and Mascardo, 1982b). To determine whether 
the catalytic activity of GRK2 was required for EGF-mediated 
centrosome separation, we expressed wild-type bovine GRK2 or 
catalytically inactive bovine GRK2-K220R in GRK2 shRNA HeLa 
cells (Figure 3D). EGF-promoted centrosomal separation was effec-
tively rescued by overexpression of wild-type GRK2 but not by 
GRK2-K220R, demonstrating that the catalytic activity of GRK2 is 
FIGURE 1: Localization of endogenous GRK2 to centrosomes. (A) Representative immunoblot demonstrating the 
expression of GRK2 in HeLa, HEK293, and MDA-MB-231 cells using a GRK2-specific monoclonal antibody (3A10). ERK2 
was used as a loading control. (B) HEK293, HeLa, and MDA-MB-231 cells were fixed and stained with anti-GRK2/3 
monoclonal and γ-tubulin polyclonal antibodies. Representative images of cells in interphase are shown from 
n > 80 cells. Arrows denote inset regions and colocalization. Scale bar, 5 μm. (C) Whole-cell (WC) HEK293 lysates 
and various fractions of the centrosomal preparation (30–70% sucrose) were electrophoresed by SDS–PAGE and 
immunoblotted for α-tubulin and GRK2 using the 3A10 monoclonal. (D) Top, control shRNA and GRK2 shRNA stably 
transfected HeLa cells were harvested and analyzed for GRK2 expression using an anti-GRK2/3 monoclonal antibody. 
Bottom, analysis of GRK2 localization in GRK2 shRNA cells. Cells were fixed and stained with anti-GRK2/3 monoclonal 
and γ-tubulin polyclonal antibodies. Note the loss of GRK2 staining in these cells. Representative images. Arrow denotes 
inset regions and colocalization. Scale bar, 5 μm. (E) Immunofluorescence performed using a polyclonal GRK2-specific 
antibody in control and GRK2 shRNA HeLa cells.
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et al., 2008). Whereas expression of wild-
type GRK2 effectively rescued EGF-pro-
moted centrosome separation, GRK2-YF 
was completely ineffective in rescuing cen-
trosome separation (Figure 5, A and B). 
These data provide strong evidence that 
EGFR phosphorylation of tyrosine residues 
in GRK2 serves as an essential link between 
EGFR and GRK2 in the EGF-promoted cen-
trosomal separation pathway.
Centrosome separation during the cell 
cycle is mediated by Plk1, which controls 
splitting of duplicated centrosomes (cen-
trosome disjunction) in late G2 by phospho-
rylating and activating Mst2, which in turn 
phosphorylates and activates Nek2A 
(Mardin et al., 2011). Therefore we tested 
whether this Plk1-Mst2-Nek2A pathway is 
also involved in EGF-promoted centrosome 
separation. Initial studies revealed that inhi-
bition of Plk1 using the Plk1 inhibitor BI 
2536 had no effect on EGF-induced cen-
trosome separation in HeLa cells (Figure 6A) 
or on the basal level of centrosome separa-
tion (data not shown). BI 2536 is a potent 
Plk1 inhibitor, with Ki ≈ 0.5 nM (Steegmaier 
et al., 2007), and was previously shown to 
effectively inhibit centrosome disjunction 
(Mardin et al., 2011) and nucleophosmin 
phosphorylation (So et al., 2012). To investi-
gate the potential involvement of Nek2A, 
Nek2A levels were knocked down by siRNA 
treatment (Figure 6B). Whereas knockdown 
of Nek2A had no significant effect on EGFR 
activation (Figure 6B), it completely attenu-
ated EGF-promoted centrosome separation 
(Figure 6D). Because the role of Nek2A in centrosomal separation 
occurs through a process involving members of the Hippo pathway, 
particularly Mst2 (Mardin et al., 2011), we next evaluated a potential 
role for Mst2 in this pathway. Similar to Nek2A, knockdown of Mst2 
had no effect on EGFR activation (Figure 6C), but it effectively at-
tenuated EGF-promoted centrosome separation (Figure 6D). Taken 
together, these results reveal an essential role for GRK2, Mst2, and 
Nek2A in EGF-promoted centrosome separation.
A hallmark of Mst2 activation involves the proteolytic cleavage 
of full-length Mst2 (∼55 kDa) to produce an active ∼34-kDa form 
(Lee et al., 2001). To determine whether Mst2 is activated by EGF 
treatment, we assessed full-length Mst2 levels over a 0- to 30-min 
treatment with EGF in control and GRK2 shRNA cells. This resulted 
in ∼40% reduction in full-length Mst2 after 30-min EGF treatment 
in control cells, whereas-full length Mst2 levels were unchanged in 
GRK2 shRNA cells (Figure 7, A and B). Thus GRK2 appears to 
mediate EGF-promoted cleavage and activation of Mst2. To test 
whether Mst2 is directly phosphorylated by GRK2, we performed 
in vitro phosphorylation reactions using purified glutathione 
S-transferase (GST)–Mst2 and GRK2. Although a significant level 
of Mst2 autophosphorylation occurred over a 30-min incubation, 
Mst2 phosphorylation was substantially increased in the presence 
of GRK2 (Figure 7C). Additional analysis of these data revealed 
that Mst2 is an effective substrate for GRK2, with a stoichiometry 
of ∼3–4 mol phosphate/mol Mst2 above the level of Mst2 auto-
phosphorylation (Figure 7C). To substantiate these findings, we 
that we previously validated (Busillo et al., 2010). These siRNAs ef-
fectively and specifically knocked down expression of either GRK2 
(Supplemental Figure S3D) or GRK5 (data not shown), and loss of 
GRK2 completely attenuated EGF-promoted centrosome separa-
tion (Supplemental Figure S3E).
To determine whether GRK2 also plays a role in EGF-promoted 
centrosome separation in nontransformed cells, we evaluated this 
process in retinal pigment epithelial 1 (RPE1) cells. GRK2 is ex-
pressed in these cells and can be effectively knocked down by siRNA 
treatment (Figure 4A). Endogenous GRK2 appears to be localized in 
centrosomes in RPE1 cells, as assessed using a polyclonal GRK2-
specific antibody (Figure 4B) or a monoclonal GRK2/3 antibody 
(data not shown). Similar to HeLa cells, knockdown of GRK2 expres-
sion in RPE1 cells had no effect on EGF-promoted activation of 
ERK1/2 phosphorylation (Figure 4C) but completely attenuated 
EGF-promoted centrosome separation (Figure 4D). Of interest, 
RPE1 cells demonstrated less centrosomal separation than that ob-
served in HeLa cells (Figure 3B). Thus GRK2 appears to play an es-
sential role in EGF-promoted centrosomal separation in both trans-
formed and nontransformed cells.
To better define the link between EGFR and GRK2 in centrosome 
separation, we compared the ability of wild-type GRK2 and a mu-
tant GRK2 (GRK2-YF) to rescue EGF-promoted centrosome separa-
tion in GRK2 shRNA cells. GRK2-YF has mutations in three tyrosine 
residues (Tyr-13, 86, and 92) that were previously shown to be phos-
phorylated by activated EGFR and result in GRK2 activation (Chen 
FIGURE 2: GRK2 is a bona fide centrosomal component. (A) Top, GFP-centrin–expressing HeLa 
cells were fixed and stained using the polyclonal GRK2 antibody. Note that GRK2 is colocalized 
with centrin. Representative images of cells in interphase. Inset, yellow arrow denotes mother 
centriole; orange arrow denotes daughter centriole. Bottom, HeLa cells were fixed and stained 
with the monoclonal GRK2 (3A10) and polyclonal pericentrin antibodies. Representative images 
of cells in interphase. (B) Quantitation of GRK2 localization with the mother (centriole with 
greater GFP-centrin expression) vs. the daughter centriole (n > 30 cells from two independent 
experiments). (C) HeLa cells pretreated with nocodazole to depolymerize microtubules were 
fixed and stained for GRK2 and γ-tubulin (n > 85 cells from two independent experiments). Note 
that colocalization remains even after microtubule depolymerization. Quantitation of the 
number of cells displaying centrosomal localization after nocodazole treatment. For all images, 
arrows denote inset regions. Scale bar, 5 μm.
Volume 24 September 15, 2013 GRK2 regulates centrosome separation | 2799 
try (LC-MS/MS). Seven sites of phosphoryla-
tion were identified, three major sites 
(Ser-18, Thr-174, and Ser-316) and four mi-
nor sites (Thr-180, Thr-252, Ser-284, and 
Thr-292; Table 1). Two of the major sites of 
GRK2 phosphorylation (Ser-18 and Ser-316) 
were previously identified as sites for Plk1 
phosphorylation of Mst2 (Mardin et al., 
2011). These studies demonstrate that 
GRK2 can directly phosphorylate Mst2 and 
there is significant overlap between the sites 
phosphorylated by GRK2 and Plk1.
To further characterize the role of Mst2 in 
the EGF pathway, we expressed catalytically 
inactive Mst2-K56R in HeLa cells. This 
mutant functioned as an effective dominant-
negative mutant and abolished EGF-
mediated centrosome separation (Figure 
8A). Because our mass spectrometry analy-
sis identified Ser-18 and 316 as two of the 
major GRK2 phosphorylation sites on Mst2 
and previous studies identified Ser-15, 18, 
and 316 as putative Plk1 phosphorylation 
sites involved in centrosome separation 
(Mardin et al., 2011), we also evaluated an 
Mst2 mutant defective in Plk1 phosphoryla-
tion in this pathway. Expression of an 
Mst2-3A (S15A, S18A, S316A) mutant in 
control cells effectively suppressed EGF-
mediated centrosome separation, whereas 
expression of wild-type Mst2 had no effect 
(Figure 8A). Taken together, these studies 
support a role for GRK2 phosphorylation of 
Mst2 residues Ser-18 and Ser-316 in EGF-
promoted centrosome separation.
DISCUSSION
In addition to their more commonly known 
role in phosphorylating activated GPCRs, 
GRKs also appear to have many additional 
functional roles (Gurevich et al., 2012). In 
this article, we demonstrate that GRK2 is lo-
calized to centrosomes and mediates EGF-
promoted separation of duplicated cen-
trosomes. The ability of GRK2 to regulate 
this pathway is both Nek2A and Mst2 de-
pendent and appears to involve direct phos-
phorylation of Mst2 by GRK2, resulting in 
Mst2 activation.
The pathway involved in centrosomal 
separation that occurs during the cell cycle 
has been extensively characterized (Mardin 
and Schiebel, 2012). Centrosomes duplicate 
once per cell cycle and normally start to separate at G2/M. Dupli-
cated centrosomes are held together by two structural proteins that 
function as a linker or tether, C-Nap1 and rootletin. The kinase 
Nek2A phosphorylates C-Nap1 and rootletin in late G2, which dis-
places these proteins from the centrosome and allows centrosome 
separation. Upstream control of Nek2A activity is mediated by two 
components of the Hippo pathway, the protein kinase Mst2 and the 
scaffolding protein hSav1 (Mardin et al., 2010). Aurora A and Plk1 
also play a critical role in this process, with Aurora A functioning to 
also evaluated the ability of GRK2 to phosphorylate purified Mst2-
K56R, a kinase-dead mutant of Mst2. There was no autophospho-
rylation of Mst2-K56R, whereas GRK2 phosphorylated Mst2-K56R 
to a stoichiometry of ∼3 mol/mol (Figure 7D). These studies dem-
onstrate that GRK2 can directly phosphorylate Mst2 and suggest 
that this phosphorylation results in Mst2 activation.
To identify the GRK2 phosphorylation sites on Mst2, we analyzed 
tryptic digests of nonphosphorylated and GRK2-phosphorylated 
Mst2-K56R using liquid chromatography-tandem mass spectrome-
FIGURE 3: Knockdown of GRK2 expression leads to inhibition of EGF-promoted centrosome 
separation in HeLa cells. (A) Knockdown of GRK2 expression and activation of EGFR, as 
indicated by ERK1/2-T202 and MEK1/2-S217 phosphorylation, after 5-min treatment with 
100 ng/ml EGF (n = 3). Calnexin (CLX) was used as a loading control. (B) Percentage of cells with 
separated duplicated centrosomes in S phase after vehicle (serum-free media) or 30-min 
treatment with 100 ng/ml EGF in control, GRK2, and GRK5 shRNA cells. *p < 0.05 (n = 6). 
(C) Separation of duplicated centrosomes in control or GRK2 shRNA cells after 0–1 h of 
100 ng/ml EGF treatment. *p < 0.05 (n = 4). (D) Expression of transiently transfected wild-type 
bovine GRK2 or GRK2-K220R in GRK2 shRNA cells. (E) Percentage of cells with separated 
duplicated centrosomes after vehicle or 30-min treatment with 100 ng/ml EGF in GRK2 shRNA 
cells transiently transfected with empty pcDNA3 vector, wild-type GRK2, or GRK2-K220R. 
*p < 0.05 (n = 4). F. Centrosomal GRK2 in unseparated or separated duplicated centrosomes, as 
detected by anti-GRK2/3 antibody, after 100 ng/ml EGF treatment for 30 min.
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Mascardo, 1982b), whereas a link between mitogen-promoted cen-
trosome separation and DNA synthesis was also proposed (Sherline 
and Mascardo, 1984). These early studies clearly demonstrated that 
mitogens such as EGF stimulate centrosome separation and help to 
coordinately link centrosome separation with DNA synthesis. In the 
present study, we started to further dissect the mechanism of this 
process and identified an essential role for GRK2, Mst2, and Nek2A 
in this pathway.
While the manuscript of this article 
was under review, Mardin et al. (2013) 
published an article demonstrating that 
EGF-mediated centrosome separation was 
Mst2 and Nek2A dependent and also 
involved hSav1, rootletin, and C-Nap1. 
Although the link between EGFR and Mst2 
was not clearly established in their study, 
they also found that the pathway was de-
pendent on Akt activation (Mardin et al., 
2013). Of interest, previous studies estab-
lished a link between Akt and Mst2 and 
showed that Akt can directly phosphorylate 
Mst2 on Thr-117 and Thr-384, although this 
phosphorylation inhibits Mst2 activity (Kim 
et al., 2010; Romano et al., 2010). Thus the 
mechanistic link between Akt activation 
and EGF-promoted centrosome separation 
activate Plk1, which in turn phosphorylates Mst2. Mst2 phosphoryla-
tion results in reduced interaction of PP1γ within an Mst2-Nek2A-
PP1γ complex, leading to enhanced ability of Nek2A to phosphory-
late C-Nap1 (Mardin et al., 2010, 2011).
The role of mitogens such as EGF in centrosomal separation was 
first described in 1982 (Sherline and Mascardo, 1982a). Additional 
studies proposed a role for calmodulin-stimulated contraction of mi-
crofilaments attached to centrosomes in this process (Sherline and 
FIGURE 5: EGF-promoted centrosome separation is mediated by tyrosine phosphorylation of 
GRK2. (A) Expression of wild-type (wt) GRK2 and GRK2-YF in GRK2 shRNA HeLa cells, detected 
using anti-GRK2 3A10 antibody. (B) Separation of duplicated centrosomes after vehicle or 
100 ng/ml EGF treatment for 30 min transfected with vector, wt GRK2, or GRK2-YF (n = 3). 
*p < 0.01 (n = 3).
FIGURE 4: GRK2 is localized to centrosomes in RPE1 cells. (A) Blotting for GRK2, using the anti-GRK2 3A10 antibody, in 
RPE1 cells transfected with control or GRK2 siRNA (n = 3). (B) Centrosomal localization of GRK2 in RPE1 cells using the 
GRK2 polyclonal antibody. (C) Expression and activation, as indicated by ERK1/2-T202 phosphorylation, of EGFR in 
RPE1 cells after vehicle or 5-min treatment with 100 ng/ml EGF (n = 3). Calnexin (CLX) was used as a loading control. 
(D) Percentage of S phase–synchronized cells with separated duplicated centrosomes after vehicle (serum-free media) or 
30-min treatment with 100 ng/ml EGF in control or GRK2 siRNA–transfected RPE1 cells. *p < 0.05 (n = 3).
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cannot rule out a potential role for Thr-174 
phosphorylation, however, since this site 
was also identified to be a major phospho-
rylation site for GRK2 in our in vitro 
analysis.
An important component in this pathway 
is the link between EGFR and GRK2. Previ-
ous studies showed that EGFR activation 
results in association of GRK2 with the EGFR 
and subsequent phosphorylation of GRK2 
at three tyrosine residues (Tyr-13, -86, and 
-92), resulting in activation of GRK2 (Chen 
et al., 2008). It is worth noting that Src also 
phosphorylates GRK2 on the same three ty-
rosines and results in GRK2 activation 
(Sarnago et al., 1999). Here we show that 
these tyrosine residues are, in fact, impor-
tant for EGF-promoted centrosome separa-
tion, as a GRK2 mutant with these residues 
mutated to Phe was not able to rescue cen-
trosomal separation in GRK2-null cells. In 
addition to direct phosphorylation of GRK2 
by EGFR, it is also possible that the EGFR 
might activate GRK2 through GPCR transac-
tivation. GPCR-EGFR cross-talk has been 
well documented (Leserer et al., 2000) and 
might even be transmitted to GPCRs local-
ized in centrosomes (Gillies et al., 2009). 
Although the source of EGFR signaling to 
centrosomal GRK2 could stem from plasma 
membrane–localized, endocytosed, or nu-
clear EGFRs (Brand et al., 2011), EGFR acti-
vation ultimately leads to activation of GRK2 
with centrosomal GRK2 being optimally lo-
calized to regulate the Mst2-Nek2A-PP1γ 
complex.
Although we did not address the func-
tional role of EGFR-promoted centrosome 
separation, recent studies suggested that activating EGFR during S 
phase might allow cells to continue into G2/M and have beneficial 
effects (Mardin et al., 2013). For example, EGF-treated cells allowed 
to progress into G2/M demonstrate decreased mitotic defects such 
as lagging chromosomes, chromosome bridges, and chromosome 
missegregation (Mardin et al., 2013). Furthermore, EGF activation 
also allows cells to bypass the requirement for the Eg5 pathway in 
mitosis, revealing a way for cancer cells to bypass potential cancer 
therapeutics targeting this pathway (Mardin et al., 2013). The fact 
that GRK2 is involved in a process that could modify mitotic spindle 
fidelity supports the potential role of GRK2 in the development of 
cancer. For example, GRK2 levels are elevated in human granulosa 
cell tumors (King et al., 2003) and thyroid cancer (Metaye et al., 
2002). Because EGFR signaling is associated with many cancers 
(Herbst, 2004), abnormal EGFR-GRK2 signaling could lead to 
unintended defects especially when activated in G1 or S phase. 
Potentially, cells with abnormal GRK2 levels may be more prone to 
genomic instability.
Overall these studies provide additional insight into the myriad 
of functions regulated by GRKs and provide a clear link between 
EGF receptors, GRK2, and regulation of the cellular machinery 
that controls centrosome separation. These results also provide 
insight into the specificity of these kinases since GRK5 is also local-
ized in centrosomes, where it has a role in regulating microtubule 
is unclear. Our work provides additional mechanistic input on this 
pathway and reveals that GRK2 can directly phosphorylate Mst2 
and likely regulate Mst2 activation. The combination of EGFR and 
GRK2 activation also results in partial cleavage of Mst2 into its 
more active conformation, a process that may be mediated by cas-
pase-3 (Deng et al., 2003). Although it is unclear how caspase-3 
might be activated under these conditions, previous studies 
showed that Mst1 can function as an upstream activator of cas-
pase-3 (Lee et al., 2001). GRK2 has also been reported to mediate 
the G2/M phase of the cell cycle (Penela et al., 2010). Given that 
we found that GRK2 does not affect centrosome separation during 
the cell cycle, however, it appears likely that GRK2 has a distinct 
functional role at different stages of the cell cycle.
LC-MS/MS analysis of GRK2-phosphorylated Mst2 revealed 
Ser-18 and Ser-316 as the likely two major phosphorylation sites in-
volved in centrosome separation. These two sites were among the 
three sites previously identified to be important for linking Mst2 
phosphorylation by Plk1 with centrosome separation in the G2 
phase (Mardin et al., 2011). Ser-18 and Ser-316 are surrounded by 
acidic residues and are thus in the preferred environment for both 
Plk1-mediated (Dephoure et al., 2008) and GRK2-mediated (Onorato 
et al., 1991) phosphorylation. We propose that GRK2 activation by 
EGFR leads to GRK2 phosphorylation of Mst2 at these sites, which, 
in turn, regulates the Mst2-Nek2A-PP1γ complex (Figure 8B). We 
FIGURE 6: EGF-activated duplicated centrosome separation is mediated by Mst2 and Nek2A in 
HeLa cells. (A) Separation of duplicated centrosomes after vehicle or 100 ng/ml EGF treatment 
with or without 60 nM BI 2536 treatment. *p < 0.05 (n = 4). (B) siRNA-mediated knockdown of 
Nek2A expression and activation of EGFR, as indicated by ERK1/2-T202 phosphorylation, after 
vehicle or 5-min treatment with 100 ng/ml EGF (n = 3). Calnexin (CLX) was used as a loading 
control. (C) siRNA-mediated knockdown of Mst2 expression and activation of EGFR, as 
indicated by ERK1/2-T202 phosphorylation, after vehicle or 100 ng/ml EGF treatment for 5 min 
(n = 3). D. Percentage of separated duplicated centrosomes, in cells transfected with control, 
Mst2 siRNA, or Nek2A siRNA, after vehicle or 100 ng/ml EGF treatment for 30 min. *p < 0.05 
(n = 3–4).
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for immunofluorescence, 1:2000 for immunoblotting; Millipore, 
Billerica, MA), anti-GRK2 3A10 (1:2000 for immunoblotting), 
anti–α-tubulin (1:1000; Sigma-Aldrich), and anti-EGFR (1:1000; 
Covance, Princeton, NJ). Polyclonal antibodies used were anti–γ-
tubulin (1:1000; Sigma-Aldrich), anti–α-tubulin (1:1000; Sigma-
Aldrich), anti-pericentrin (1:2000; Abcam, Cambridge, MA), anti-
GRK2 (1:100 for immunofluorescence, 1:1000 for immunoblotting; 
Santa Cruz Biotechnology, Santa Cruz, CA), anti-Mst2 (1:2000; 
Cell Signaling Technology), and anti–ERK-pT202/Y204 and 
antixpMEK1/2-pS217/S221 (1:2000; Cell Signaling Technology). 
Secondary antibodies for immunofluorescence were from Invitro-
gen (Carlsbad, CA) and included Alexa Fluor 488 goat anti-mouse, 
Alexa Fluor 594 goat anti-mouse, Alexa Fluor 488–conjugated 
goat anti-rabbit, Alexa Fluor 594–conjugated goat anti-rabbit, 
and Alexa Fluor 633–conjugated goat anti-rabbit, all used at 
1:100 dilution. Secondary antibodies for immunoblotting were 
from Vector Laboratories (Burlingame, CA).
nucleation (Michal et al., 2012). Although it is unclear whether GP-
CRs have a role in regulating GRK function in centrosomes, several 
GPCR signaling components, including GPCRs (Gillies et al., 2009), 
Gi (Cho and Kehrl, 2007), and β-arrestins (Shankar et al., 2010), are 
found in centrosomes. Further characterizing the potential links 
between GPCRs and centrosomal function should provide impor-
tant insight into the regulation of cell function. Moreover, target-
ing the EGFR-GRK2 pathway may be important in helping to treat 
cancers mediated by aberrant EGFR signaling.
MATERIALS AND METHODS
Materials
Nocodazole, cytochalasin B, hydroxyurea, and thymidine were 
purchased from Sigma-Aldrich (St. Louis, MO). Calyculin A was 
from Cell Signaling Technology (Danvers, MA). Monoclonal anti-
bodies used were anti-Nek2 (1:2000; BD Biosciences, San Jose, 
CA), anti–γ-tubulin (1:1000; Sigma-Aldrich), anti-GRK2/3 (1:100 
FIGURE 7: Mst2 is activated by the EGFR-GRK2 pathway in HeLa cells. (A, B) Decrease in full-length Mst2 from 
0–30 min of EGF treatment in control shRNA cells. *p < 0.05 (n = 4). (C) Time course of in vitro phosphorylation of 
GST-Mst2 by GRK2 (n = 3) and quantitation of Mst2 phosphorylation in the presence or absence of GRK2. (D) In vitro 
phosphorylation of purified Mst2-K56R by GRK2 for 60 min and quantitation of Mst2-K56R phosphorylation in the 
presence or absence of GRK2.
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TAGAAACAGAAT-3′) along with a scrambled control shRNA (Sigma-
Aldrich) were transfected into HeLa cells using Lipofectamine 2000 
(Invitrogen). Cells were then selected in 2 μg/ml puromycin to ob-
tain a stably expressing population. For GRK2 siRNA transfection, 
four independent GRK2 siRNAs (5′-GGGACGUGUUCCA-
GAAAUU-3′, 5′-GCUCGCAUCCCUUCUCGAA-3′, 5′-GGAAU-
CAAGUUACUGGACA-3′, and 5′-GCGAUAAGUUCACACGGUU-3′) 
Cell culture
HeLa and HEK293 cells were cultured in DMEM (Mediatech, 
Manassas, VA) supplemented with 10 mM 4-(2-hydroxyethyl)-1-pip-
erazineethanesulfonic acid (HEPES) and 10% fetal bovine serum 
(FBS; GIBCO, Invitrogen). MDA-MB-231 cells were grown in MEM 
(Mediatech) supplemented with 10 mM HEPES and 10% FBS. RPE1 
cells were cultured in DMEM:F12 medium (Mediatech) with 10% 
FBS. HeLa cells with stable GRK knockdown were grown in DMEM 
supplemented with 10 mM HEPES, 10% FBS, and 2 μg/ml puromy-
cin. HeLa cells stably expressing GFP-centrin were a generous gift 
from Timothy Yen (Fox Chase Cancer Center, Philadelphia, PA) and 
were cultured in DMEM supplemented with 10 mM HEPES, 10% 
FBS, and 800 μg/ml G418. The GFP-centrin signal of the daughter 
centriole was ∼40% that of the mother centriole.
For cell synchronization, double-thymidine block was used for 
G1/S-phase synchronization, and hydroxyurea treatment was used 
for S-phase synchronization and to promote centrosome duplica-
tion. For double-thymidine block, HeLa cells were plated at 25% 
confluency, blocked in media containing 2 mM thymidine for 16 h, 
released for 9–12 h into fresh medium, and then blocked a second 
time with 2 mM thymidine for 16 h. Cells were then released into 
fresh medium and the appropriate time points collected. For hy-
droxyurea block, HeLa cells were plated at 70% confluency and 
blocked in media containing 2 mM hydroxyurea for 48 h. Samples 
were prepared, and standard immunoblotting procedures were fol-
lowed. Flow cytometry was similar to that described previously 
(Michal et al., 2012).
DNA constructs, siRNAs, and shRNAs
HA-Mst2 and Flag-Mst2-K56R were obtained from Addgene 
(Cambridge, MA). HA-Mst2-3A (S15A, S18A, and S316A) was a gen-
erous gift of Elmar Schiebel (University of Heidelberg, Heidelberg, 
Germany).
To create stable cell lines, shRNA constructs specific to GRK2 















aPrimary sequence of phosphopeptides identified on the basis of MS/MS spec-
tra; pS, phosphoserine; pT, phosphothreonine.
bRelative abundance of the identified phosphopeptide was estimated from 
the MS/MS spectra counting method. —, not present; +, low counts; ++ high 
counts.
cNonphosphorylated kinase-dead mutant Mst2-K56R purified from Sf9 cells.
dPhosphorylated in the presence of GRK2 kinase-dead mutant Mst2-K56R.
eOwing to no coverage of this area in the MS/MS spectra of Mst2-K56R, the 
abundance of this phosphopeptide was estimated from the MS/MS spectra of 
tryptic proteolytic digests of GST-Mst2 WT. No phosphorylation of this peptide 
was found in the autophosphorylated form of GST-Mst2 WT.
TABLE 1: Identified tryptic phosphopeptides from Mst2-K56R.
FIGURE 8: GRK2 phosphorylation of Mst2 mediates EGF-mediated 
centrosomal separation. (A) Decrease in separation of duplicated 
centrosomes mediated by overexpression of Mst2-K56R (n = 3) or 
Mst2-3A (n = 5) with or without 30-min treatment with EGF 
(100 ng/ml) in HeLa cells. *p < 0.05. (B) Model for centrosome 
separation mediated by EGFR in G1/S phase and Plk1 in G2 phase.
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Microtubule nucleation assay
HeLa cells with stable GRK2 knockdown were treated for 1 h with 
10 μg/ml nocodazole to completely depolymerize microtubules. To 
assess microtubule regrowth, cells were washed twice with warm 
media to remove nocodazole and incubated at 37°C for 5 min. Cells 
were then fixed and stained with anti-rabbit pericentrin and anti-
mouse α-tubulin antibodies. Images were taken of at least 80 cells 
from four independent experiments using a Nikon Eclipse E800 
fluorescence microscope, and each aster was treated independently. 
Only asters nucleated from either single or paired duplicated 
centrosomes were analyzed. Aster areas (μm2) were obtained by 
drawing a region around the aster and measuring the area of this 
region. Images were quantified using QED camera software (Media 
Cybernetics) and processed with Image-Pro Plus.
In vitro kinase assay
GRK2 was purified as described (Kunapuli et al., 1994), and purified 
GST-Mst2 was from Sigma-Aldrich. Purified Mst2-K56R prepared 
from Sf9 cells was a generous gift from Elmar Schiebel (University of 
Heidelberg, Heidelberg, Germany). Protein phosphorylation assays 
were similar to previous protocols (Pronin et al., 1997). For reactions 
involving GST-Mst2, ∼50 nM purified GST-Mst2 was incubated with 
or without 50 nM purified GRK2 for 5–30 min at 30°C in a buffer 
containing 20 mM Tris-HCl, pH 7.5, 2 mM EDTA, 7.5 mM MgCl2, 
100 μM ATP. and [γ-32P]ATP (250–1000 cpm/pmol ATP). Reactions 
were stopped with SDS sample buffer and electrophoresed on 10% 
SDS–polyacrylamide gel. Proteins were visualized by autoradiogra-
phy, and phosphorylation stoichiometries were determined by ex-
cising bands from the dried gels and counting in a scintillation 
counter.
A similar protocol was used with purified Mst2-K56R, and al-
though initial studies revealed that Mst2 is a substrate for GRK2, the 
stoichiometry of phosphate incorporation was only ∼0.8 mol phos-
phate/mol Mst2. LC-MS/MS analysis identified multiple sites of 
basal phosphorylation on Mst2-K56R, suggesting that Mst2-K56R is 
a substrate of insect cell kinases when expressed in Sf9 cells. To re-
move these phosphates, the protein was treated with lambda phos-
phatase according to the manufacturer’s protocol (New England 
BioLabs, Ipswich, MA). Briefly, 1.2 μM Mst2-K56R was incubated 
with 1600 U of recombinant lambda phosphatase in lambda phos-
phatase buffer (50 mM HEPES, pH 7.5, 100 mM NaCl, 2 mM dithio-
threitol, 0.01% Brij35) with 1 mM MnCl2 at 30°C for 30 min, and the 
reaction was stopped by adding 1 μl of PhosSTOP solution (Roche) 
to 160 μl of reaction mixture. Dephosphorylated Mst2-K56R was 
then isolated by incubation with 20 μl of nickel-nitriloacetic acid 
Sepharose beads for 1 h at 4°C while rocking, followed by elution 
and overnight dialysis against 20 mM Tris, pH 7.5, 2 mM MgCl2, and 
50 mM NaCl. The dephosphorylated Mst2-K56R was then incu-
bated with 1 μM GRK2 for 60–90 min at 30°C using the buffer condi-
tions described for GST-Mst2 phosphorylation. GRK2 phosphory-
lated Mst2-K56R was then subjected to LC-MS/MS analysis to 
identify the specific sites of GRK2 phosphorylation. It is important to 
note that the phosphatase treatment removed all basal phosphates 
on Mst2-K56R except for a low level of phosphate on Ser-316. Incu-
bation of Mst2-K56R with GRK2, however, significantly enhanced 
phosphorylation of Ser-316, based on comparison of MS/MS spec-
tra counts before and after treatment with GRK2 (Table 1).
Tandem mass spectrometry
LC-MS/MS analyses were performed at the Wistar Institute Pro-
teomics Facility (Philadelphia, PA). Gel bands containing Mst2 pro-
teins were excised, digested with trypsin, and analyzed using an 
were pooled, and 60 pmol of the pool was used per transfection. 
For GRK5 siRNA transfection, four independent GRK5 siRNAs 
(5′-CCAACACGGUCUUGCUGAA-3′, 5′-GGGAGAACCAUUCCAC-
GAA-3′, 5′-CAAACCAUGUCAGCUCGAA-3′, and 5′-GAUUAUG-
GCCACAUUAGGA-3′) were pooled and 60 pmol of the pool was 
used per transfection. For Mst2 and Nek2A, 5′-GGAUAGUU-
UUUCAAAUAGG-3′ was used to knock down Mst2 expression 
(Matallanas et al., 2007), and 5′-TTCTGAGAGTCAGCTCACA-3′ 
was used for Nek2A (Fletcher et al., 2005). Control siRNA–scram-
bled sequences were purchased from Thermo Fisher Scientific 
(Waltham, MA).
Fractionation and immunoblotting
For immunoblotting, cells were pelleted by centrifugation, lysed in 
Triton lysis buffer (0.2 mM HEPES, pH 7.4, 1% Triton X-100, 0.5 M 
NaCl, 10 mM EDTA, containing protease inhibitors and PhosSTOP 
phosphatase inhibitor tablets [Roche, Indianapolis, IN]) for 20 min on 
ice and then centrifuged at 18,000 × g for 30 min at 4°C. Samples 
were loaded onto 10% SDS–PAGE gels, transferred to nitrocellulose 
membranes, and blocked in 5% nonfat milk in Tris-buffered saline 
(TBS; 20 mM Tris-HCl, pH 7.5, 150 mM NaCl) with 0.1% Tween-20. 
Blots were incubated with primary antibody overnight at 4°C, washed 
in TBS with 0.1% Tween-20, and incubated with appropriate second-
ary antibody for 1 h at room temperature. Blots were then washed 
extensively and developed with either West PICO or DURA Chemilu-
minescence Kit (Pierce, Rockford, IL). For Mst2 immunoblotting, cells 
were pretreated for 5 min with 1 μM calyculin A in phosphate-buff-
ered saline (PBS) and then lysed as described. Protein concentrations 
were determined by Bradford assay. Centrosome preparations were 
made following the procedure of Bornens and Moudjou (1999).
Immunofluorescence microscopy
For all immunofluorescence studies, cells were split onto poly-l-
lysine–coated coverslips 24–72 h before fixation/staining. For all 
antibodies, except γ-tubulin when used alone, cells were first preex-
tracted with 1% Triton X-100 in PBS for 30 s. For samples used for 
centrosomal separation and duplication analyses, only methanol 
fixation was used, followed by blocking with 1% bovine serum albu-
min/PBS overnight. To costain for endogenous GRK2 (3A10 mono-
clonal antibody) and γ-tubulin (polyclonal antibody), cells were pre-
extracted with 1% Triton X-100 in PBS for 30 s, fixed in 4% 
paraformaldehyde in PBS for 10 min, and permeabilized with meth-
anol for 10 min. To costain for GRK2, using a polyclonal GRK2 anti-
body or GRK2/3 monoclonal antibody, and γ-tubulin or pericentrin, 
cells were preextracted with 1% Triton X-100 in PBS, fixed in metha-
nol for 20 min at −20°C, and then rehydrated in PBS for 10 min at 
room temperature. For all GRK2 antibodies, after fixation, slides 
were incubated with quench buffer (PBS, 2.5% nonfat milk, 150 mM 
sodium acetate) and block buffer (PBS, 0.1% Tween-20, 2.5% nonfat 
milk) at room temperature and the appropriate primary antibodies 
overnight at 4°C. Slides were then washed with PBS, incubated with 
the designated secondary antibodies for 1 h at room temperature, 
and washed with PBS with 0.1% Tween-20. DNA was stained with 
4′,6-diamidino-2-phenylindole (Molecular Probes, Eugene, OR) and 
slides mounted with Pro-Long Anti-Fade (Molecular Probes). Images 
were taken using either a Zeiss LSM 510 META confocal microscope 
with a Plan-Apo 63× 11.4 oil immersion lens (Carl Zeiss, Jena, 
Germany) or a Nikon Eclipse E800 fluorescence microscope (Nikon, 
Melville, NY). All intensity and area analysis was performed using 
MetaMorph software (Molecular Devices, Sunnyvale, CA), Image-
Pro Plus (Media Cybernetics, Rockville, MD), or ImageJ (National 
Institutes of Health, Bethesda, MD).
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LTQ-Orbitrap XL mass spectrometer as described previously (Beer 
et al., 2011; Fong et al., 2011). Peptide sequences were interpreted 
from MS/MS spectra by searching against a human database con-
taining Mst2 and common contaminant sequences using Bioworks, 
version 3.3.1 SP1 (Thermo Fisher Scientific). All database searches 
allowed for up to two missed cleavages, a static modification of Cys 
with iodoacetamide, and the following dynamic modifications: Met 
oxidation, Asn deamidation, and Ser, Thr, and Tyr phosphorylation. 
Outputs from Bioworks searches were filtered using mass tolerance 
of 10 ppm and DCn > 0.05, and identified phosphorylated peptides 
were manually verified.
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